Pliant Therapeutics, Inc. Price Today
Pliant Therapeutics, Inc.
PLRX
Healthcare
$1.19B
💰
Market Cap
0
💸
Price to Earnings
$-2.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Strong_buy Consensus
Buy |
10 |
Strong Buy |
9 |
Hold |
1 |
Sell |
0 |
Strong Sell |
0 |
PLRX Price Forecast Target
20.1 👉 63.0 +213%
PLRX EPS Forecast
-2.8 👉 -3.3 +19%
Financials
Profit Margin
0 %
Revenue Growth
6.6 %
Dividend
$ 0
Held Percent
5.9% - Insiders
98.0% - Institutions
-3.9% - Public
Major Fund Holders
-
💰 FMR, LLC $120.5M
-
💰 Deep Track Capital, LP $91.0M
-
💰 CHI Advisors LLC $79.8M
-
💰 Redmile Group, LLC $77.8M
-
💰 Avidity Partners Management, LP $70.9M
Stock Ideas
Carl Icahn Portfolio
With a staggering net worth exceeding $16 billion, Icahn has made a lasting impact on the stock market as the founder and manager of Icahn Enterprises. Known as a 'corporate raider,' Icahn has gained fame for his relentless pursuit of undervalued co…
Bill Ackman Portfolio
Bill Ackman, a renowned investor, has established himself as a long-term value investor with a keen eye for short-term price fluctuations. His expertise lies in special situations investments, and his Pershing Square portfolio reflects a highly conc…
Scott Ferguson Portfolio
With a strong background as a protégé of Bill Ackman, founder of Pershing Square Capital Management, Scott Ferguson has honed his skills and expertise in the art of activist investing. He possesses the ability to identify undervalued companies with …
Nancy Pelosi Portfolio
Nancy Pelosi is the Speaker of the United States House of Representatives and a savvy investor. Her personal portfolio is heavily weighted towards large-cap tech stocks, such as Apple and Microsoft. She also owns shares in several consumer staples a…📮FAQ
Some Frequently Asked Questions.
The Pliant Therapeutics, Inc. industry is Biotechnology
The Pliant Therapeutics, Inc. sector is Healthcare
The Pliant Therapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -6.0
The Pliant Therapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Pliant Therapeutics, Inc. is $1.19B
There are total of 44983743 float shares with 98.0% held by Institutions and 5.9% held by insiders
The MPliant Therapeutics, Inc. forecasted Earnings per Share EPS is $-3.3
The Pliant Therapeutics, Inc. Earnings per Share EPS is -2.8
The Pliant Therapeutics, Inc. company has $9685000 gross profits with 0 profit margins
The Pliant Therapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Pliant Therapeutics, Inc. Revenue is $9768000 with 0.066 revenue growth
The price target for Pliant Therapeutics, Inc. stock is $63.0 for the high target and $24.0 for the low target
The consensus analyst recommendations for Pliant Therapeutics, Inc. is Strong_buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Pliant Therapeutics, Inc. is Strong_buy, with the following breakdown:
- Buy: 10
- Strong Buy: 9
- Hold: 1
- Sell: 0
- Strong Sell: 0
The Beta of Pliant Therapeutics, Inc. is 1.2
The dividend of Pliant Therapeutics, Inc. is $0
The dividend yield of Pliant Therapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Pliant Therapeutics, Inc. stock are
- FMR, LLC
- Deep Track Capital, LP
- CHI Advisors LLC
- Redmile Group, LLC
The Pliant Therapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0